This quarter is the first quarter of 2016 where the average price of the portfolio has gone up. Not much, only 3,4 % compared to a overall portfolio performance of -23.1 % in 2016. The best performing share is Fortnox, fast recovering after the failed take-over bid from Norwegian-based Visma. Fortnox is up 46 % in Q3. The worst performing share is by far CybAero. Q3 more than halved the price of the share. CybAero is down 52 %. The reason is the issue announced mid-September. Continue reading
The past week Dignitana, BrainCool, Heliospectra and CybAero have issued their half year reports. All four companies have products, on-going sales and are aiming to penetrate their markets. BrainCool have made their first turnover in Q2. For an investor the development of sales, both in terms of turnover and growth are the focal point. To make it short: I’m a bit disappointed.
Furthermore, in 2016 8 out of 11 companies in my portfolio have made issues, and after the reports we will probably see 2 more in the next couple of months. Continue reading
Well, the portfolio performance the past six months have been depressing and the overall performance is rather poor. On the other hand, it seems that at least for a few of the companies early summer has been a turning point.
In overall, the average share price in the portfolio is down 23 % during the first six months of 2016. In Q2, the average is minus 14.7 %. In comparison, the SPI-index (all Nasdaq-shares in Sweden) is down 4.3 % in 2016 and down 1.3 % in Q2. Compared to the performance of the portfolio in 2015, where the full-year result was +78.6%, 2016 seem dull and depressing. Check the December update for details. Continue reading
Start-ups like Phase Holographic Imaging needs money, often lots of money to develop. There are different ways to get the money. First option: bank-loan. Unfortunately, this is often at a high interest rate since there are few assets and low security in a start-up – and then the company will fight to pay the loan back. In general, borrowed money makes it harder to achieve break even. Next two options are to ask the current investors or the public for the money. When they ask the current owners, it is a share issue with preferential rights – and a public issue when shares are offered to whoever wants to invest. The fourth possibility is to find an investor or a group of investors willing to invest in the company and make a private placing. So funding comes from either the bank, the current owners or new investors.
Friday January 29th Phase Holographic announced a double-issue totalling 40 MSEK. 25 MSEK will come in through a preferential rights issue and 15 MSEK via a private placement. The issue price for both is 23 SEK. In the preferential rights issue the current owners can buy 1 new share for each 9 shares they have. If an investor holds 900 shares, he or she is entitled to buy 100 new shares at a price of 23 SEK each. Investors must own shares Wednesday February 24th to have this right to new shares. Continue reading
December was a green month – in more than one sense. The weather was warm and my lawn seemed to grow in both November and December, but more interesting the predominant colour in my portfolio performance for December is green.
In this post, I will evaluate the portfolio performance in December (and in 2015) and give a few comments of what to expect in 2016. The performance first. Continue reading
I might need the services of Sherlock Holmes, and I guess that Dr. Watson would record this peculiar case as: The mystery of the vanished Shares. Some of my shares seems simply to have vanish into thin air.
The shares in question are Photocat shares. As readers of this blog knows, I participated in the IPO of Photocat in October. The share is at First North Stockholm, and trading began more than two weeks ago on Friday November 20th. Unfortunately, and this is why I might need to acquire the services of Mr. Holmes, the shares are not yet in my possession after more than two weeks. Continue reading
Some of my shares have been on a temporary leave the past weeks. My investment strategy is long-term and passive, but the past weeks I have made a revision towards a slightly more active approach. IVISYS was in fact the trigger. Continue reading
The past weeks have been good to my portfolio. In general shares have gone up, and some quite a lot. The short news this week will follow up on new developments in AroCell, IVISYS, Recyctec, Phase Holographic and a new company on this blog: A1M Pharma which came by as a surprise, even to me. Continue reading
October was a fine month. Autumn was at its best and a few mornings with white, frosty grass reminds me that winter will soon be over us with darkness and rain. Still it is mild, and leaves are still on the trees, both green, brown, and yellow. Even a modest storm or a night of frost, may rapidly change this.
Luckily, my portfolio performed better in October than in August and September. Some shares went even exceptionally well – Phase Holographic + 94 % – and others bled – Dignitana 24 % and Recyctec – 20 %. Continue reading
The past two weeks I have been busy with a lot of different things – but not my share portfolio. I tend to monitor it closely, but a vacation in Germany without wifi followed by a week with a seminar leaving three days for five days of work – my share portfolio was not the first thing to check when I got home. Nevertheless there is a handful of portfolio news. Continue reading